drug

DSG3-CAART

Phase 2updated 3mo ago

by $CABA Cabaletta Bio, Inc.

Phase 2

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying DSG3-CAART

phase2A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)recruitingn=40

News(0)

no news has mentioned this drug yet

Data sources

ClinicalTrials.gov

last refreshed 20m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

DSG3-CAART

Phase 2updated 3mo ago

by $CABA Cabaletta Bio, Inc.

Phase 2

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying DSG3-CAART

phase2A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)recruitingn=40

News(0)

no news has mentioned this drug yet

Data sources

ClinicalTrials.gov

last refreshed 20m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

DSG3-CAART

all catalysts(0)

Trials studying DSG3-CAART

News(0)

Report a data issue

comments(0)

DSG3-CAART

all catalysts(0)

Trials studying DSG3-CAART

News(0)

Report a data issue

comments(0)